非癌性肺组织18F-FDG-PET/CT摄取作为免疫检查点抑制剂所致间质性肺病的预测指标
回顾性纳入165例原发肺癌患者,分析ICI治疗前3个月内FDG-PET/CT非癌性肺摄取与ICI-ILD的关系。高NCL-TGA1.0(≥149.45)与ILD发生独立相关(OR 6.588,p=0.002),高NCL-TGA1.0组2年累积发生率58.4% vs 低组14.4%(p<0.001)。
要点
- NCL-TGA1.0≥149.45是ICI-ILD的独立危险因素,OR 6.588(p=0.002)。
- 高NCL-TGA1.0组2年ILD累积发生率58.4%,低组14.4%(p<0.001)。
- FDG-PET/CT非癌性肺高摄取或可作为ICI治疗前风险分层工具。
核心结论
- 非癌性肺FDG-PET/CT高摄取与ICI-ILD发生相关,或可作为原发肺癌ICI治疗前的风险分层工具。
研究设计与样本
- 回顾性研究,纳入165例原发肺癌患者,均为ICI治疗前3个月内接受FDG-PET/CT者;利用人工智能从原发肿瘤对侧肺提取非癌性肺区域,计算NCL-SUVmax、NCL-SUVmean及NCL-TGA(NCL-SUVmean×NCL体积[mL]),其中NCL-SUVmean和NCL-TGA采用0.5、1.0、1.5、2.0四个SUV阈值计算。
诊断标准与关键数值
- 单因素分析显示NCL-SUVmax、NCL-SUVmean2.0(SUV阈值=2.0)和NCL-TGA1.0(SUV阈值=1.0)高值与ILD发生显著相关(均p=0.003);多因素分析校正年龄、肿瘤FDG摄取和既存间质性肺异常后,高NCL-TGA1.0(≥149.45)与ILD发生独立相关(OR 6.588,p=0.002)。
临床应用与阅片要点
- 原文结论认为非癌性肺FDG-PET/CT高摄取与ICI-ILD发生相关,或可作为原发肺癌ICI治疗前的风险分层工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Immune checkpoint inhibitors (ICIs) have improved lung cancer prognosis; however, ICI-related interstitial lung disease (ILD) is fatal and difficult to predict. Herein, we hypothesized that pre-existing lung inflammation on radiological imaging can be a potential risk factor for ILD onset. Therefore, we investigated the association between high uptake in noncancerous lung (NCL) on 18F- FDG-PET/CT and ICI-ILD in lung cancer.
METHODS: Patients with primary lung cancer who underwent FDG-PET/CT within three months prior to ICI therapy were retrospectively included. Artificial intelligence was utilized for extracting the NCL regions (background lung) from the lung contralateral to the primary tumor. FDG uptake by the NCL was assessed via the SUVmax (NCL-SUVmax), SUVmean (NCL-SUVmean), and total glycolytic activity (NCL-TGA)defined as NCL-SUVmean×NCL volume [mL]. NCL-SUVmean and NCL-TGA were calculated using the following four SUV thresholds: 0.5, 1.0, 1.5, and 2.0.
RESULTS: Of the 165 patients, 28 (17.0%) developed ILD. Univariate analysis showed that high values of NCL-SUVmax, NCL-SUVmean2.0 (SUV threshold=2.0), and NCL-TGA1.0 (SUV threshold=1.0) were significantly associated with ILD onset (all p = 0.003). Multivariate analysis adjusted for age, tumor FDG uptake, and pre-existing interstitial lung abnormalities revealed that a high NCL-TGA1.0 (≥149.45) was independently associated with ILD onset (odds ratio, 6.588; p = 0.002). Two-year cumulative incidence of ILD was significantly higher in the high NCL-TGA1.0 group than in the low group (58.4% vs. 14.4%; p < 0.001).
CONCLUSION: High uptake of NCL on FDG-PET/CT is correlated with ICI-ILD development, which could serve as a risk stratification tool before ICI therapy in primary lung cancer.
引用
- Yamazaki M, Watanabe S, Tominaga M, et al. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors. Acad Radiol. 2024. PMID: 39227217. doi:10.1016/j.acra.2024.08.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。